Lenci, E., Cantini, L., Pecci, F., Cognigni, V., Agostinelli, V., Mentrasti, G., . . . Berardi, R. (2021). The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. J Clin Med.
Citação norma ChicagoLenci, Edoardo, et al. "The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated With First-Line Pembrolizumab." J Clin Med 2021.
ציטוט MLALenci, Edoardo, et al. "The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated With First-Line Pembrolizumab." J Clin Med 2021.